Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SIBIA Neurosciences (SIBI) -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (349)	5/26/1999 9:23:00 AM
From: scaram(o)uche	Read Replies (2) \| Respond to of 579

We need some guidance. I presume that royalties ass'd with the option would be very, very high. This may be a good sign..... Lilly has come back, and they have an existing license agreement with SIBI for certain VGCC compounds. So much we don't know. Very, very tight-to-the-vest company...... I love it. "We will also be advancing compounds already identified at SIBIA that are active on nicotinic acetylcholine receptor subtypes." This agreement could bring in milestones relatively quickly, IMO.